Clinical efficacy of secukinumab in the treatment of psoriasis
Objective To observe the clinical efficacy of skunkizumab in the treatment of psoriasis,evaluate the changes of psychological state of patients with psoriasis.Methods Patients with moderate and severe psoriasis in our hospital were selected as the research object and randomly divided into control group and observation group with 75 cases in each group.The control group was given calcipotriol ointment,and the observation group was given skukiyuzumab by subcutaneous injection at the 0 th,1 st,2 nd,3 rd and 4 th weeks,with a dose of 300mg each time,and then the dose was maintained once every 4 weeks,all patients were treated for 8 weeks.Before and after treatment,the patients' disease severity(PASI score)and mental state(HAMA score,HAMD score)were evaluated,and the changes of blood vessels in the lesions were observed by dermatoscope.Results The total clinical effective rate of the group using skukiyuzumab 98.67%(74/75)was significantly higher than that of the control group 81.33%(61/75)(χ2=12.43,P＜0.05);After 8 weeks of treatment,the scores of Hama and Hamd in the observation group were significantly lower than those in the control group(P＜0.05);and the number of vessels and the diameter of vessels in psoriatic lesions were decreased,and the changes of vessels in the observation group were more obvious than those in the control group(P＜0.05).Conclusion Secukinumab has significant curative effect in the treatment of moderate to severe plaque psoriasis,and the effect is fast,without obvious adverse reactions,and can significantly improve the anxiety and depression state of patients.There are significant changes in vascular manifestation under dermoscopy,it can be used to follow-up during treatment and guide treatment.
万方数据
维普
